NCT04776525
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma
At risk: Primary completion moved at least 1 year 2 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 2026 to Dec 2027
- Eligibility criteria expanded, about 37 words
- Study completion pushed from Sep 2036 to Dec 2037
- Secondary endpoints: details revised at 1 of 2 entries
- Notable Primary completion date: Sep 2024 to Sep 2026
- Study completion date: Sep 2034 to Sep 2036
- Minor Site details revised at 1 of 2 sitesv5
- Minor Start date changed from estimate of Mar 2021 to Apr 27, 2021
- Site contacts updated at 1 of 2 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall response rate
Timeframe: Up to 16 weeks
Secondary (2)
Incidence of treatment-related adverse events as assessed by CTCAE v5.0 and dose reductions (safety and tolerability)
Correlation between TP53 mutation assessed by sequencing of tumor DNA and overall response
Arms and interventions
Sequential ifosfamide and doxorubicinExperimental
Four cycles ifosfamide 9 g/m2 and four cycles doxorubicin 80 mg/m2. Each cycle has a duration of 14 days.
Drugs: Ifosfamide, Doxorubicin
Sites
2 sites in 1 country